Last reviewed · How we verify
MF nasal spray
MF nasal spray is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing mucus production.
MF nasal spray is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing mucus production. Used for Allergic rhinitis (seasonal and perennial), Non-allergic rhinitis, Nasal polyps.
At a glance
| Generic name | MF nasal spray |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
The active ingredient is mometasone furoate, a potent intranasal corticosteroid that binds to glucocorticoid receptors in nasal tissue, inhibiting inflammatory mediator release and reducing edema. This mechanism provides symptomatic relief of allergic and non-allergic rhinitis by decreasing nasal congestion, rhinorrhea, and sneezing.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Non-allergic rhinitis
- Nasal polyps
Common side effects
- Headache
- Pharyngitis
- Epistaxis
- Nasal irritation
- Dysgeusia
Key clinical trials
- Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis (PHASE4)
- Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419) (PHASE3)
- Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332) (PHASE3)
- Safety and Efficacy of Mometasone Furoate (SCH 032088) vs Beclomethasone Dipropionate or Placebo in Seasonal Allergic Rhinitis (C93-013) (PHASE3)
- A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512) (PHASE3)
- Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (PHASE3)
- Effect of Mepolizumab in Severe Bilateral Nasal Polyps (PHASE3)
- Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MF nasal spray CI brief — competitive landscape report
- MF nasal spray updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI